Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Combined with Adebrelimab or Dalpiciclib in Neoadjuvant Breast Cancer
NCT05132790Active, not recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label trial of adebrelimab and dalpiciclib in breast cancer (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Pathological Complete Response up to 11 months and Residual Cancer Burden 0-I Index up to 11 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
adebrelimabdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05132790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132790.